Yes, we can...
Help the world’s 200 million people with diabetes
live healthier lives

Around the world, some 200 million people are living with diabetes–a figure that the World Health Organization (WHO) estimates will grow to 300 million by 2025. While developed countries have a serious problem, diabetes in much of the developing world is becoming an epidemic. In China, there are an estimated one million new cases a year, while India–with more than 40 million people with diabetes–has the greatest number of cases in the world. More than 90 percent of new cases are type 2 diabetes, an unwanted outcome of emerging countries’ increasing prosperity and their citizens’ adoption of more sedentary lifestyles and richer diets.
     Clearly, diabetes is a large and rapidly growing problem with long-term consequences and complications for world health.
     BD plays a unique and vital role in the care of people with diabetes by providing insulin delivery products and training programs on a global basis. BD serves the needs of people with diabetes not only through its role as a supplier, but also by spreading best practices globally through partnerships with government and nongovernmental agencies and other companies. The Company’s education and training programs help people with diabetes manage their disease.
     BD is focused on providing high-quality, reliable and easy-to-use insulin delivery products. “Our objective is to make billions of devices with perfect quality at the lowest possible cost while never allowing the supply of these devices to be interrupted, even as the need grows at an increasing pace,” says Bill Marshall, President, BD Medical–Diabetes Care. Another priority is continuous innovation to make insulin delivery more comfortable and convenient. The BD Ultra-Fine III Mini Pen Needle, for instance, is the shortest pen needle in the world and can be used by both children and adults.



In the United States... The
BD Diabetes Makeover Program,
a comprehensive approach to improving
the lives of people with diabetes, expanded
to North General Hospital in East Harlem.
With East Harlem at the epicenter of
the diabetes epidemic in New York City,
the program demonstrates the value of medication,
devices, fitness, nutrition, lifestyle management
and the importance of a coordinated team approach
to treating diabetes.

BD Pen Needles are compatible with diabetes pens
and dosers sold worldwide, including those by Eli Lilly
and Company and sanofi-aventis, as shown here.


In China... BD is teaming with Project HOPE, the Chinese Ministry of Health and industry partners in the China Diabetes Education Program, a long-term effort to train healthcare providers to care for diabetes patients. Since 1998, the program has trained nearly 1,600 healthcare providers from 812 healthcare centers. Dr. Ji LiNong at the Beijing People’s Hospital has been part of this program for over seven years. In turn, these trainees have trained more than 37,000 healthcare providers and more than 165,000 people with diabetes and their family members in all of China’s 31 provinces. Partnering with China’s government is the best way to provide long-term sustainability for the program.

   The BD Ultra-Fine II Short Needle Insulin
   Syringe is scaled in half-unit markings,
   allowing for precise dosage.


BD offers three sizes of
BD Ultra-Fine Pen Needles:
12.7mm, 8mm and 5mm.
In Ireland... Six Sigma, lean business processes and product and process validation are enabling BD’s Dun Laoghaire plant to produce two billion high-quality diabetes pen needles annually– a number that is expected to double by 2010. This commitment to product excellence and innovation helps ensure that BD syringes and pen needles consistently deliver high quality, comfort and ease of use to people with diabetes who rely upon them. Lancets, also used in diabetes care, are produced by the BD plant in Drogheda.